- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04046991
Treating Primary Progressive Aphasia (PPA) Using High-definition tDCS
Treating Primary Progressive Aphasia (PPA) and Elucidating Neurodegeneration in the Language Network Using Transcranial Direct Current Stimulation (tDCS)
Study Overview
Status
Conditions
Detailed Description
The central framework for the project is a double-blind, sham-controlled, crossover study in which subjects with the non-fluent/agrammatic and logopenic variants of primary progressive aphasia (naPPA and lvPPA, respectively) will undergo language testing and structural and functional brain imaging before and after receiving 10 semi-consecutive daily sessions of real or sham high definition transcranial direct current stimulation (HD-tDCS) paired with modified constraint-induced language therapy (mCILT). Language testing and brain imaging will be repeated immediately after completion of and 3 months following completion of treatment.
Subjects with naPPA and lvPPA will be randomized to one of two study arms: HD-tDCS+mCILT or sham stimulation+mCILT paired with pre- and post-stimulation imaging and behavioral measures. Equal numbers of subjects with naPPA and lvPPA will be randomized to the HD-tDCS + mCILT and sham + mCILT study arms. The study is double-blinded, in that neither the subject nor the study personnel administering HD-tDCS or sham stimulation will know which arm of the study the subject has been randomized into. Study coordinators will administer HD-tDCS by entering a pre-determined code that has been programmed into the device by another member of the study team. Data will be digitally audio-recorded and analyzed off-line, such that study team members performing data coding and analysis will likewise be blinded to the treatment condition of each subject.
Subject participation in this protocol will occur during 27 planned visits that will span approximately 8 months. The events of the study visits are described below:
VISIT 1:
a Informed consent and screening b. Baseline language assessment #1 c. Baseline MRI scanning
VISIT 2:
Baseline language assessment #2
VISITS 3-11:
HD-tDCS+mCILT OR sham stimulation+mCILT, depending on the study arm to which they had been randomized.
VISIT 12:
- Final session of HD-tDCS+mCILT or sham stimulation+mCILT
- Follow-up language assessment
- Follow-up MRI
VISIT 13:
6-Week follow-up language assessment
VISIT 14:
- 12-week follow-up language assessment
- 12-week follow-up MRI
**CROSSOVER**
VISIT 15:
Crossover baseline language assessment #2
VISITS 16-24:
HD-tDCS+mCILT or sham stimulation+mCILT
VISIT 25:
- 10th session of HD-tDCS+mCILT or sham stimulation+mCILT
- Follow-up language assessment
- Follow-up MRI
VISIT 26:
6 Week follow-up language assessment:
VISIT 27:
- 12-week follow-up language assessment
- 12-week follow-up MRI
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Presence of aphasia attributable to nonfluent agrammatic PPA (naPPA) or logopenic variant PPA (lvPPA)
- High school education (or more)
- Must be able to understand the nature of the study, and give informed consent
- Native English speaker
Exclusion Criteria:
- Presence of additional neurological illness such as stroke or traumatic brain injury
- Diagnosis of epilepsy or reoccurening seizures
- Pacemaker or ICDs
- Craniotomy or skull breech
- Small vessel disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: HD-tDCS+mCILT
Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of HD-tDCS for 20 minutes using a montage in which a central electrode (1.5mA) is placed over the left frontotemporal area and four surrounding cathodes (.375mA each).
Subjects will participate in a modified constraint-induced language therapy.
|
High definition transcranial direct current stimulation (HD-tDCS) involves the application of low-intensity current through electrodes placed on the scalp.
It is believed to elicit brain effects by producing incremental shifts in the resting membrane potential of large numbers of neurons, which alters neuronal firing rates and thus modulates patterns of brain activity in potentially behaviorally-relevant ways.
HD-tDCS differs from conventional transcranial direct current stimulation (tDCS) because it employed smaller electrodes configured in such a way as to deliver more focal stimulation of the brain.
Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output.
Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve.
MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
|
|
Sham Comparator: Sham+mCILT
Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of sham for 20 minutes using a montage in which a central electrode is placed over the left frontotemporal area and four surrounding cathodes.
Subjects will participate in a modified constraint-induced language therapy,
|
High definition transcranial direct current stimulation (HD-tDCS) involves the application of low-intensity current through electrodes placed on the scalp.
It is believed to elicit brain effects by producing incremental shifts in the resting membrane potential of large numbers of neurons, which alters neuronal firing rates and thus modulates patterns of brain activity in potentially behaviorally-relevant ways.
HD-tDCS differs from conventional transcranial direct current stimulation (tDCS) because it employed smaller electrodes configured in such a way as to deliver more focal stimulation of the brain.
Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output.
Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve.
MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Western Aphasia Battery Aphasia Quotient (WAB-AQ)
Time Frame: Baseline, 2 weeks, 6 weeks, 12 weeks, 14 weeks, 18 weeks, 24 weeks
|
The primary outcome measure will be the change in score on the WAB-AQ, a score assessing overall aphasia recovery.
Scores can range from 0-100.
0-25 is very severe, 26-50 is severe, 51-75 is moderate, and 76-above is mild.
A score of 93 or higher is considered recovered.
|
Baseline, 2 weeks, 6 weeks, 12 weeks, 14 weeks, 18 weeks, 24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Roy H Hamilton, MD, University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Dementia
- Communication Disorders
- Language Disorders
- Speech Disorders
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Aphasia
- Aphasia, Primary Progressive
Other Study ID Numbers
- 834650
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Progressive Aphasia
-
Maya HenryNational Institutes of Health (NIH); National Institute on Aging (NIA)RecruitingSemantic Dementia | Logopenic Progressive Aphasia | Nonfluent Aphasia, Progressive | Logopenic Variant Primary Progressive Aphasia | Semantic Variant Primary Progressive Aphasia (svPPA) | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Progressive Aphasia | Logopenic Progressive Aphasia... and other conditionsUnited States
-
Maya HenryNational Institute on Aging (NIA)RecruitingLogopenic Variant Primary Progressive Aphasia | Progressive Aphasia | Logopenic Progressive Aphasia (LPA) | Primary Progressive Aphasia(PPA) | Logopenic Variant of Primary Progressive Aphasia (LPA) | Progressive Aphasia in Alzheimer's DiseaseUnited States
-
Massachusetts General HospitalCompletedLogopenic Variant Primary Progressive Aphasia | Non-Fluent Primary Progressive AphasiaUnited States
-
Johns Hopkins UniversityNational Institute on Aging (NIA)RecruitingPrimary Progressive Aphasia | Logopenic Progressive Aphasia | Non-Fluent Primary Progressive AphasiaUnited States, Canada
-
Mayo ClinicNational Institute on Deafness and Other Communication Disorders (NIDCD)RecruitingPrimary Progressive Aphasia | Apraxia of Speech | PPA | Non-fluent Aphasia | Primary Progressive Non-fluent AphasiaUnited States
-
University of Texas at AustinUniversity of California, San Francisco; National Institute on Deafness and...Active, not recruitingPrimary Progressive Aphasia | Aphasia | Semantic Dementia | Logopenic Progressive Aphasia | Semantic Memory Disorder | Nonfluent Aphasia, Progressive | Aphasia, ProgressiveUnited States
-
University of Texas at AustinNational Institute on Deafness and Other Communication Disorders (NIDCD)Enrolling by invitationPrimary Progressive Aphasia | Aphasia | Semantic Dementia | Logopenic Progressive Aphasia | Semantic Memory Disorder | Nonfluent Aphasia, Progressive | Aphasia, ProgressiveUnited States
-
Massachusetts General HospitalNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedLogopenic Variant Primary Progressive Aphasia | Non-fluent Variant Primary Progressive Aphasia | Semantic Variant Primary Progressive AphasiaUnited States
-
IRCCS San RaffaeleEnrolling by invitationPrimary Progressive Aphasia(PPA)Italy
-
Mayo ClinicCompletedPrimary Progressive Aphasia | Aphasia | Semantic Dementia | Apraxia of Speech | Primary Progressive Nonfluent Aphasia | PPA | Non-fluent Aphasia | Progressive AphasiaUnited States
Clinical Trials on high-definition transcranial direct current stimulation
-
Anhui Medical UniversityCompletedDepressive Disorder | Functional Magnetic Resonance Imaging | Transcranial Direct Current StimulationChina
-
Anhui Medical UniversityRecruitingAnxiety | Magnetic Resonance Imaging | Transcranial Direct Current StimulationChina
-
The University of Texas at DallasUniversity of Texas Southwestern Medical CenterCompletedMemory Disorders | Word Finding DifficultyUnited States
-
South China Normal UniversityCompletedSocial Anxiety DisorderChina
-
Nanjing Medical UniversityNot yet recruitingAnxiety Disorders | High-definition Transcranial Direct Current StimulationChina
-
University of Texas Rio Grande ValleyActive, not recruitingSpinal Cord Diseases | Spinal Cord InjuriesUnited States
-
Anhui Medical UniversityRecruitingTranscranial Direct Current Stimulation | Non Suicidal Self InjuryChina
-
WANG KAICompletedHealthy Adults | Transcranial Direct Current StimulationChina
-
Istituti Clinici Scientifici Maugeri SpAUniversity of Palermo; University of Milano Bicocca; IRCCS ISMETT PalermoRecruiting
-
Anhui Medical UniversityRecruitingTranscranial Magnetic Stimulation | Functional Magnetic Resonance Imaging | Refractory Epilepsy | Transcranial Direct Current Stimulation | EEGChina